NASDAQ:XENE Xenon Pharmaceuticals (XENE) Stock Price, News & Analysis $37.04 -0.52 (-1.38%) Closing price 04:00 PM EasternExtended Trading$37.03 -0.01 (-0.01%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Xenon Pharmaceuticals Stock (NASDAQ:XENE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Xenon Pharmaceuticals alerts:Sign Up Key Stats Today's Range$36.81▼$37.9750-Day Range$33.49▼$58.6552-Week Range$33.38▼$72.66Volume1.08 million shsAverage Volume1.39 million shsMarket Capitalization$3.58 billionP/E RatioN/ADividend YieldN/APrice Target$71.15Consensus RatingModerate Buy Company Overview Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for neurological disorders. The company’s research emphasizes ion channels, proteins that help regulate the electrical activity of nerve cells. Its lead program is azetukalner, formerly known as XEN1101, an oral Kv7 potassium-channel opener being developed for seizure disorders, including focal epilepsy. Xenon is also advancing other drug candidates aimed at neurological conditions. Founded in 1996, Xenon is headquartered in Burnaby, British Columbia, and conducts drug development activities in North America. Its work includes discovering and developing therapies intended to address conditions with significant unmet medical needs.AI Generated. May Contain Errors. Read More Xenon Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreXENE MarketRank™: 3.0187645528 of 5 starsXenon Pharmaceuticals scored higher than 60% of companies evaluated by MarketBeat, and ranked 346th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingXenon Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on no strong buy ratings, 11 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialXenon Pharmaceuticals has a consensus price target of $71.15, representing about 91.9% upside from its current price of $37.09.Amount of Analyst CoverageXenon Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Xenon Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Xenon Pharmaceuticals are expected to decrease in the coming year, from ($4.63) to ($4.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenon Pharmaceuticals is -7.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenon Pharmaceuticals is -7.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenon Pharmaceuticals has a P/B Ratio of 3.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.85% of the float of Xenon Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverXenon Pharmaceuticals has a short interest ratio ("days to cover") of 6.36.Change versus previous monthShort interest in Xenon Pharmaceuticals has recently increased by 0.20%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXenon Pharmaceuticals does not currently pay a dividend.Dividend GrowthXenon Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.2 / 5News Sentiment-0.01 News SentimentXenon Pharmaceuticals has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Xenon Pharmaceuticals this week, compared to 5 articles on an average week. Company Ownership4.4 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of Xenon Pharmaceuticals in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $1,255,353.00 in company stock, which represents 0.0350% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Xenon Pharmaceuticals insiders have bought 294.79% more of their company's stock than they have sold. Specifically, they have bought $1,681,200.00 in company stock and sold $425,847.00 in company stock.Percentage Held by Insiders2.91% of the stock of Xenon Pharmaceuticals is held by insiders.Percentage Held by Institutions95.45% of the stock of Xenon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xenon Pharmaceuticals' insider trading history. Receive XENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XENE Stock News HeadlinesJPMorgan Chase & Co. Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock PriceNovember 19 at 1:12 AM | americanbankingnews.comHC Wainwright Has Negative Outlook for XENE FY2026 EarningsNovember 14, 2026 | americanbankingnews.comWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.November 20 at 1:00 AM | Porter & Company (Ad)Xenon Reports Q3 Results; Expects X-NOVA2 Data In December And Advances Pain Programs Toward Phase 2November 10, 2026 | rttnews.comXenon (XENE) Q3 2026 Earnings Call TranscriptNovember 10, 2026 | finance.yahoo.comXenon plans X-FIRST study in Q1 2027 as AZK NDA advances, with $1.2B cash into 2029November 9, 2026 | seekingalpha.comXenon Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 9, 2026 | marketscreener.comMIs Xenon Pharmaceuticals (XENE) Above Fair Value After Phase 2 Progress?November 9, 2026 | finance.yahoo.comSee More Headlines XENE Stock Analysis - Frequently Asked Questions How have XENE shares performed this year? Xenon Pharmaceuticals' stock was trading at $44.82 at the beginning of the year. Since then, XENE shares have decreased by 17.3% and is now trading at $37.0850. How were Xenon Pharmaceuticals' earnings last quarter? Xenon Pharmaceuticals Inc. (NASDAQ:XENE) released its earnings results on Monday, November, 9th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, topping the consensus estimate of ($1.13) by $0.02. Read the conference call transcript. When did Xenon Pharmaceuticals IPO? Xenon Pharmaceuticals (XENE) raised $44 million in an IPO on Friday, October 17th 2014. The company issued 4,000,000 shares at $10.00-$12.00 per share. Who are Xenon Pharmaceuticals' major shareholders? Top institutional investors of Xenon Pharmaceuticals include State Street Corp (2.13%), Pictet Asset Management Holding SA (1.52%), American Century Companies Inc. (0.99%) and Marshall Wace LLP (0.93%). Insiders that own company stock include Ian Mortimer, Gary Patou, Sherrington Robin, Andrea Difabio, Steven Gannon, Gillian Cannon, Christopher John Kenney and Sherry Aulin. View institutional ownership trends. How do I buy shares of Xenon Pharmaceuticals? Shares of XENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xenon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xenon Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Ford Motor (F), Micron Technology (MU) and AbbVie (ABBV). Company Calendar Last Earnings11/09/2026Today11/20/20269th Annual Evercore ISI HealthCONx Conference12/01/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 XENE's financial health is in the Red zone, according to TradeSmith. XENE has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:XENE CIK1582313 Webwww.xenon-pharma.com Phone(604) 484-3300Fax604-484-3450Employees364Year Founded1996Price Target and Rating Average Price Target for Xenon Pharmaceuticals$71.15 High Price Target$97.00 Low Price Target$46.00 Potential Upside/Downside+92.4%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($4.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$345.91 million Net MarginsN/A Pretax MarginN/A Return on Equity-39.81% Return on Assets-37.98% Debt Debt-to-Equity RatioN/A Current Ratio21.19 Quick Ratio21.19 Sales & Book Value Annual Sales$7.50 million Price / Sales476.71 Cash FlowN/A Price / Cash FlowN/A Book Value$11.86 per share Price / Book3.12Miscellaneous Outstanding Shares96,670,000Free Float93,853,000Market Cap$3.58 billion OptionableOptionable Beta0.11 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:XENE) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same ec...Porter & Company | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredA little-known law has been quietly applied to your savings for years.Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.